Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002495 · ClinicalTrials.gov registry record · Phase 3
SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT00002495 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 348 participants.
The verdict
NCT00002495, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without doxorubicin and vinblastine in treating patients with stage I or stage II Hodgkin's disease.
Interventions
- DRUG vinblastine
- DRUG doxorubicin hydrochloride
- RADIATION standard subtotal nodal irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 1992-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002495
The ClinicalTrials.gov registry entry for NCT00002495 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which vinblastine is the first listed.
NCT00002495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002495 about?
NCT00002495 is a clinical study titled "SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without doxo...
What is the current status of trial NCT00002495?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 1992-09. Estimated completion is 2014-04.
What interventions are being tested in trial NCT00002495?
The interventions under investigation include: vinblastine (DRUG), doxorubicin hydrochloride (DRUG), standard subtotal nodal irradiation (RADIATION).
Who is sponsoring clinical trial NCT00002495?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.